GBT Global Blood Therapeutics Inc

Price (delayed)

$42.60

Market cap

$2.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.04

Enterprise value

$2.38B

Sector: Healthcare
Industry: Biotechnology

Highlights

GBT's revenue is up by 46% since the previous quarter
Global Blood Therapeutics's gross profit has increased by 46% from the previous quarter
Global Blood Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.4% QoQ
The debt has soared by 56% year-on-year and by 48% since the previous quarter
GBT's equity is down by 28% YoY and by 9% QoQ

Key stats

What are the main financial stats of GBT
Market
Shares outstanding
62.16M
Market cap
$2.65B
Enterprise value
$2.38B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.33
Price to sales (P/S)
21.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.21
Earnings
Revenue
$123.8M
EBIT
-$237.74M
EBITDA
-$226.92M
Free cash flow
-$220.62M
Per share
EPS
-$4.04
Free cash flow per share
-$3.6
Book value per share
$6.73
Revenue per share
$2.02
TBVPS
$11.8
Balance sheet
Total assets
$724M
Total liabilities
$307.85M
Debt
$227.99M
Equity
$416.16M
Working capital
$553.13M
Liquidity
Debt to equity
0.55
Current ratio
8
Quick ratio
7.35
Net debt/EBITDA
1.19
Margins
EBITDA margin
-183.3%
Gross margin
98.4%
Net margin
-200%
Operating margin
-197.2%
Efficiency
Return on assets
-34.4%
Return on equity
-52.3%
Return on invested capital
-57.3%
Return on capital employed
-36.9%
Return on sales
-192%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GBT stock price

How has the Global Blood Therapeutics stock price performed over time
Intraday
-2.07%
1 week
-11.86%
1 month
-10.3%
1 year
-34.68%
YTD
-1.64%
QTD
-1.64%

Financial performance

How have Global Blood Therapeutics's revenue and profit performed over time
Revenue
$123.8M
Gross profit
$121.82M
Operating income
-$244.16M
Net income
-$247.55M
Gross margin
98.4%
Net margin
-200%
Global Blood Therapeutics's operating margin has surged by 99% YoY and by 43% QoQ
The net margin has soared by 98% year-on-year and by 40% since the previous quarter
GBT's revenue is up by 46% since the previous quarter
Global Blood Therapeutics's gross profit has increased by 46% from the previous quarter

Growth

What is Global Blood Therapeutics's growth rate over time

Valuation

What is Global Blood Therapeutics stock price valuation
P/E
N/A
P/B
6.33
P/S
21.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.21
The EPS has grown by 13% from the previous quarter and by 12% YoY
GBT's equity is down by 28% YoY and by 9% QoQ
The P/B is 27% above the 5-year quarterly average of 5.0 but 8% below the last 4 quarters average of 6.9
GBT's price to sales (P/S) is 75% lower than its last 4 quarters average of 83.5
GBT's revenue is up by 46% since the previous quarter

Efficiency

How efficient is Global Blood Therapeutics business performance
The ROS has soared by 98% YoY and by 41% from the previous quarter
The company's return on equity fell by 22% YoY but it rose by 4.6% QoQ
The ROA has grown by 10% from the previous quarter and by 6% YoY
The company's return on invested capital rose by 3.4% QoQ

Dividends

What is GBT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GBT.

Financial health

How did Global Blood Therapeutics financials performed over time
Global Blood Therapeutics's total assets is 135% higher than its total liabilities
Global Blood Therapeutics's total liabilities has increased by 42% YoY and by 32% QoQ
Global Blood Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.4% QoQ
The debt is 45% smaller than the equity
The debt to equity has soared by 120% YoY and by 62% from the previous quarter
The debt has soared by 56% year-on-year and by 48% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.